The Recherche Hospitalo-Universitaire (RHU) project, funded by the Investments for the Future programme (« Programme des Investissements d'Avenir »), aims to boost the transfer of scientific innovations to healthcare practice by promoting the establishment of a continuum between fundamental and clinical research. By involving the academic, hospital and corporate sectors, HHR projects aim to improve patient care, strengthen understanding of diseases and promote the emergence of more effective and tolerated treatments.
Aix-Marseille University coordinates 3 RHU projects:
The EPINOV and PIONeeR projects are among the 10 HRU projects selected in France in 2017 (wave 3) and have a budget of €5.8M and €8.5M respectively, for a period of 5 years.
The INNOV-CKD project is one of the 15 winners selected in 2019 (wave 4) and has a budget of €5.08M for 5 years.
Coordinated by Professor Fabrice Bartoloméi, this project focuses on the use of large-scale modelling of epileptogenic networks to guide surgical strategies. It consists of a multicenter trial involving 11 epilepsy surgery centers in France, using neuroinformatic brain simulation technology developed by the researchers. This project involves five partners: AMU, INSERM, AP-HM, Hospices civils de Lyon and Dassault Systèmes.
Read more about it :
Coordinated by Professor Fabrice Barlési, PIONeeR consists in evaluating the brakes in immunotherapy treatments for lung cancer. The consortium is made up of 9 partners: Aix-Marseille Université, CNRS, Inserm, AP-HM, Institut Paoli-Calmettes, Léon Bérard centre, and the companies AstraZeneca, Innate-Pharma, HalioDX, Imcheck Therapeutics.
This project aims to :
- Decipher the complex mechanisms of resistance to inhibitory antibodies at the immune control point;
- Develop new therapeutic combinations;
- Expand the range of immunomodulatory drugs in lung cancer;
- Providing new diagnostic and therapeutic options for these patients.
- RHU the Pioneer Project | Overcoming resistance to anti-PD1(L1) immunotherapies in lung cancer: first patient enters clinical trial
Coordinated by Professor Laurent Bonello, of the Cardiology Department of the North Hospital (AP-HM), this project aims to develop innovative, automated methods that can be used in clinical practice to predict the individual risk of coronary complications in patients with chronic renal disease. The cause of myocardial infarction, acute coronary syndrome affects 100,000 people in France and 800,000 in the United States each year. In 20 to 40% of cases, it concerns patients with chronic renal failure. This project brings together recognized experts in vascular biology, nephrology and cardiology and leading manufacturers in the production of innovative hemostasis tests.
The consortium is coordinated by Aix-Marseille Université, the C2VN research unit (Inserm, INRAE, AMU), in partnership with AP-HM and industrial partners BioCytex and Stago.
Read more about it:
Project Officer Transfer with the socio-economic and cultural world
Tél : 04 86 13 61 74 – email : email@example.com